All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Scorr-Insert

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Symphogen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

DENMARK Denmark

Post An Enquiry

BIO International Convention

Participation Not Confirmed

Update your events

Servier Agrees to Buy Symphogen to Swell its Cancer Pipeline

Contact the Supplier

Lead Product(s): Sym021

Therapeutic Area: Oncology

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Servier Canada Inc

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition April 03, 2020

Details:

Servier will gain full ownership of Symphogen’s proprietary pipeline of oncology and immuno-oncology programs and Symphogen’s antibody discovery and development platform.

Scandion Oncology

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

DENMARK Denmark

Post An Enquiry

BIO International Convention

Participation Not Confirmed

Update your events

SCO-101 works in synergy with the chemotherapy drug docetaxel in drug resistant cancer cells

Contact the Supplier

Lead Product(s): SCO-101

Therapeutic Area: Oncology

Highest Development Status: Phase I Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 25, 2020

Details:

Based on modelling of preclinical data with docetaxel resistant cancer cells, Scandion Oncology has published that SCO-101 significantly increases the potency of docetaxel.